GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Ending Cash Position

TME Pharma NV (FRA:0N6A) Ending Cash Position : €3.24 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Ending Cash Position?

TME Pharma NV's Ending Cash Position for the quarter that ended in Dec. 2024 was €3.24 Mil.

TME Pharma NV's quarterly Ending Cash Position increased from Dec. 2023 (€2.25 Mil) to Jun. 2024 (€2.70 Mil) and increased from Jun. 2024 (€2.70 Mil) to Dec. 2024 (€3.24 Mil).

TME Pharma NV's annual Ending Cash Position declined from Dec. 2022 (€4.63 Mil) to Dec. 2023 (€2.25 Mil) but then increased from Dec. 2023 (€2.25 Mil) to Dec. 2024 (€3.24 Mil).

TME Pharma NV Ending Cash Position Historical Data

The historical data trend for TME Pharma NV's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Ending Cash Position Chart

TME Pharma NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.30 9.46 4.63 2.25 3.24

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 3.01 2.25 2.70 3.24

TME Pharma NV Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TME Pharma NV's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.245+0.995
=3.24

TME Pharma NV's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.703+0.537
=3.24

TME Pharma NV Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Ending Cash Position
Comparable Companies
XPAR:ALOPM XPAR:ALTAO XPAR:ALINT XPAR:ALBPS XPAR:ALTHX XPAR:ALVIO XPAR:ALMDP XPAR:ALPAT XPAR:ALNEV XPAR:ALNFL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ALTME:France
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
Website
https://www.tmepharma.com
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines